Acute CholangitisNCT02601417
The Necessity of Bile Cultures in Patients With Acute Cholangitis
A study testing Ignoring result of bile culture in people with Acute Cholangitis, run by Seoul National University Hospital at 1 site in South Korea.
Trial summary
Acute cholangitis with obstructive jaundice is a condition which needs biliary drainage and appropriate antibiotics. Bile culture is an optional laboratory test according to 2013, 2018 Tokyo guideline, but the clinical significance is yet unproven. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Acute Cholangitis
- What is being tested?
- Ignoring result of bile culture
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 440 participants
- Where
- 1 siteSouth Korea
- Study dates
- 27 Aug 2015to 30 Jul 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
The inclusion criteria
(1) patients aged ≥20 years with suspected or confirmed acute cholangitis according to the 2013 and 2018 Tokyo guidelines
The exclusion criteria
- inability to provide informed consent
- no evidence of acute cholangitis diagnostics as per the guidelines
- development of organ failure before random allocation or organ failure by non-cholangitis causes
- undergoing bile culture tests after the onset of organ failure
- failure to have bile or blood culture tests
- patients who were already administered antibiotics for other conditions
- unsuccessful PTBD insertion
- failure to achieve complete bile drainage via PTBD
Trial locations and contacts
1 site in 1 country.
About this study
Acute cholangitis with obstructive jaundice is a condition which needs biliary drainage and appropriate antibiotics. Bile culture is an optional laboratory test according to 2013, 2018 Tokyo guideline, but the clinical significance is yet unproven. And its results might indicate less information of the true pathogen regarding normal flora. Previous study conducted at our institute found drug-resistant pathogens identified in bile culture had no impact on the outcome. So the investigators are conducting a multicenter randomized controlled trial comparing groups which considers both blood and bile culture as control and which considers only blood culture as trial group in order to prove bile culture provides no additional helpful clinical information.
Read the detailed description
The investigators conducted a nationwide, prospective, multicenter, subject blinded, noninferiority RCT. Patients with acute cholangitis who met the specific inclusion criteria were enrolled. All the participants underwent a percutaneous transhepatic biliary drainage (PTBD) procedure to provide adequate drainage, and both bile and blood cultures were collected. A culture study was performed after obtaining the initial bile from the bile duct assessment during PTBD insertion. In this study, the patients who were conducted endoscopic retrograde cholangiopancreatography (ERCP) and biliary drainage were excluded to avoid unintended contamination by normal flora of gastrointestinal tract.
Initially, empirical broad-spectrum antibiotics, including metronidazole combined with third-generation cephalosporins or quinolones were administered for treating acute cholangitis. All participants provided informed consent after explaining the study details. Participants who consented to participate were then randomized.
The investigators recruited patients aged ≥20 years with suspected or confirmed acute cholangitis according to the 2013 and 2018 Tokyo guidelines. The exclusion criteria were (1) inability to provide informed consent, (2) no evidence of acute cholangitis diagnostics as per the guidelines, (3) development of organ failure before random allocation or organ failure by non-cholangitis causes, (4) undergoing bile culture tests after the onset of organ failure, (5) failure to have bile or blood culture tests, (6) patients who were already administered antibiotics for other conditions, (7) unsuccessful PTBD insertion, and (8) failure to achieve complete bile drainage via PTBD.
Empirical antibiotic therapy was initially conducted for both groups of patients. In the control group, the initial antibiotic regimen was maintained if both blood and bile cultures were negative or if all identified organisms were sensitive to empirical treatment. However, the empirical antibiotics were switched to appropriate antibiotics considering the results from blood and bile cultures if any organism demonstrated resistance. In experimental group, the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group.
Following antibiotic modification in the experimental and control groups, additional biliary drainage procedures (ERCP or PTBD) were performed for considering ineffective drainage on the discretion of physicians.
The investigators carried out a per-protocol analysis that excluded patients who had received antibiotics prior to PTBD, which could have altered the microbial profile, those with lethal adverse events before the confirmation of blood or bile culture results, and those who had been administered changed antibiotics for infectious diseases other than acute cholangitis.
Student's t-test was used to analyze continuous variables with normal distribution, Mann-Whitney U-test was performed otherwise. Categorical variables were assessed with the chi-square test or Fisher's exact test. A p-value of ≤0.05 indicated significant differences, and the respective variables were regarded as covariates for adjustment in each analysis. Student's t-test and Mann-Whitney U-test were used to compare mortality and hospital stay duration. All the tests were two-sided, and a p-value of <0.05 was regarded as statistically significant. In the analyses of binary outcomes, the results are presented as point estimates for the between-group differences in the proportion of patients. The two-sided 95% confidence interval (CI) for these differences was calculated using the Wald method.
- Conditions
- Acute Cholangitis
- Being tested
- Ignoring result of bile culture
- Keywords
- Cholangitis, Bile culture, percutaneous transhepatic biliary drainage
- Medical subject headings
- Cholangitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ignoring result of bile cultureOther
the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group
| Study group | Role | What they receive |
|---|---|---|
| Antibiotics change is based on both blood and bile cultures | No intervention | Empirical antibiotic therapy was initially conducted for patients. In the control group, the initial antibiotic regimen was maintained if both blood and bile cultures were negative or if all identified organisms were sensitive to empirical treatment. However, the empirical antibiotics were switched to appropriate antibiotics considering the results from blood and bile cultures if any organism demonstrated resistance. Following antibiotic modification in the experimental and control groups, additional biliary drainage procedures (ERCP or PTBD) were performed for considering ineffective drainage on the discretion of physicians. |
| Antibiotics change is based only on the blood culture | Experimental | Empirical antibiotic therapy was initially conducted for patients. In experimental group, the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group.
Following antibiotic modification in the experimental and control groups, additional biliary drainage procedures (ERCP or PTBD) were performed for considering ineffective drainage on the discretion of physicians. Receives: Other: Ignoring result of bile culture |
What is being measured
The primary outcome is the main question the study is designed to answer.
Organ Failure
Shock, AKI, altered mentality, Acute respiratory distress
Measured: during hospitalization and empirical antibiotic administration. (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months)
Secondary outcomes (3)
Hospital days
The duration of hospital stay covered the period from randomization to discharge for the management of acute cholangitis
Measured: through study completion, an average of 1 month
Re-intervention for biliary drainage
The frequency of reintervention for biliary drainage was the proportion of patients undergoing additional procedures during the study period.
Measured: through study completion, an average of 1 month
Mortality
Mortality rate was the proportion of patients experiencing death during the study period.
Measured: through study completion, an average of 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Nov 2015 (estimated)
- Study start27 Aug 2015
- Primary completion20 Mar 2024
- Study completion30 Jul 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute CholangitisStudies of the same condition, open and under way.
- More trials run by Seoul National University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 440 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Seoul National University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sang Hyub Lee, Seoul National University Hospital
- Investigators
- Sang Hyub Lee, MD. PhD., Principal investigator, Department of internal medicine and liver research institute, Seoul national university hospital, Seoul, Korea
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02601417
- Sponsor's protocol ID
- 2015-1452
- Status last verified
- May 2024
- First submitted
- 27 Aug 2015
- Last updated
- 30 May 2024
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Necessity of Bile Cultures in Patients With Acute Cholangitis
- ClinicalTrials.gov ID
- NCT02601417
- Acronym / sponsor ID
- 2015-1452
- Conditions
- Acute Cholangitis
- Keywords
- Cholangitis, Bile culture, percutaneous transhepatic biliary drainage
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 440 participants (estimated)
- Lead sponsor
- Seoul National University HospitalUniversity, hospital or other
- Study start
- 27 Aug 2015 (actual)
- Primary completion
- 20 Mar 2024 (actual)
- Study completion
- 30 Jul 2024 (estimated)
- First posted
- 10 Nov 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Acute cholangitis with obstructive jaundice is a condition which needs biliary drainage and appropriate antibiotics. Bile culture is an optional laboratory test according to 2013, 2018 Tokyo guideline, but the clinical significance is yet unproven. And its results might indicate less information of the true pathogen regarding normal flora. Previous study conducted at our institute found drug-resistant pathogens identified in bile culture had no impact on the outcome. So the investigators are conducting a multicenter randomized controlled trial comparing groups which considers both blood and bile culture as control and which considers only blood culture as trial group in order to prove bile culture provides no additional helpful clinical information.
Detailed description
The investigators conducted a nationwide, prospective, multicenter, subject blinded, noninferiority RCT. Patients with acute cholangitis who met the specific inclusion criteria were enrolled. All the participants underwent a percutaneous transhepatic biliary drainage (PTBD) procedure to provide adequate drainage, and both bile and blood cultures were collected. A culture study was performed after obtaining the initial bile from the bile duct assessment during PTBD insertion. In this study, the patients who were conducted endoscopic retrograde cholangiopancreatography (ERCP) and biliary drainage were excluded to avoid unintended contamination by normal flora of gastrointestinal tract.
Initially, empirical broad-spectrum antibiotics, including metronidazole combined with third-generation cephalosporins or quinolones were administered for treating acute cholangitis. All participants provided informed consent after explaining the study details. Participants who consented to participate were then randomized.
The investigators recruited patients aged ≥20 years with suspected or confirmed acute cholangitis according to the 2013 and 2018 Tokyo guidelines. The exclusion criteria were (1) inability to provide informed consent, (2) no evidence of acute cholangitis diagnostics as per the guidelines, (3) development of organ failure before random allocation or organ failure by non-cholangitis causes, (4) undergoing bile culture tests after the onset of organ failure, (5) failure to have bile or blood culture tests, (6) patients who were already administered antibiotics for other conditions, (7) unsuccessful PTBD insertion, and (8) failure to achieve complete bile drainage via PTBD.
Empirical antibiotic therapy was initially conducted for both groups of patients. In the control group, the initial antibiotic regimen was maintained if both blood and bile cultures were negative or if all identified organisms were sensitive to empirical treatment. However, the empirical antibiotics were switched to appropriate antibiotics considering the results from blood and bile cultures if any organism demonstrated resistance. In experimental group, the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group.
Following antibiotic modification in the experimental and control groups, additional biliary drainage procedures (ERCP or PTBD) were performed for considering ineffective drainage on the discretion of physicians.
The investigators carried out a per-protocol analysis that excluded patients who had received antibiotics prior to PTBD, which could have altered the microbial profile, those with lethal adverse events before the confirmation of blood or bile culture results, and those who had been administered changed antibiotics for infectious diseases other than acute cholangitis.
Student's t-test was used to analyze continuous variables with normal distribution, Mann-Whitney U-test was performed otherwise. Categorical variables were assessed with the chi-square test or Fisher's exact test. A p-value of ≤0.05 indicated significant differences, and the respective variables were regarded as covariates for adjustment in each analysis. Student's t-test and Mann-Whitney U-test were used to compare mortality and hospital stay duration. All the tests were two-sided, and a p-value of <0.05 was regarded as statistically significant. In the analyses of binary outcomes, the results are presented as point estimates for the between-group differences in the proportion of patients. The two-sided 95% confidence interval (CI) for these differences was calculated using the Wald method.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Antibiotics change is based on both blood and bile cultures | No intervention | –Empirical antibiotic therapy was initially conducted for patients. In the control group, the initial antibiotic regimen was maintained if both blood and bile cultures were negative or if all identified organisms were sensitive to empirical treatment. However, the empirical antibiotics were switched to appropriate antibiotics considering the results from blood and bile cultures if any organism demonstrated resistance. Following antibiotic modification in the experimental and control groups, additional biliary drainage procedures (ERCP or PTBD) were performed for considering ineffective drainage on the discretion of physicians. |
| Antibiotics change is based only on the blood culture | Experimental | Other: Ignoring result of bile cultureEmpirical antibiotic therapy was initially conducted for patients. In experimental group, the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group. Following antibiotic modification in the experimental and control groups, additional biliary drainage procedures (ERCP or PTBD) were performed for considering ineffective drainage on the discretion of physicians. |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ignoring result of bile culturethe antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group | Other | Antibiotics change is based only on the blood culture |
Primary outcome
Organ Failure
Time frame: during hospitalization and empirical antibiotic administration. (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months)
Shock, AKI, altered mentality, Acute respiratory distress
3 secondary outcomes
Hospital days
Time frame: through study completion, an average of 1 month
Re-intervention for biliary drainage
Time frame: through study completion, an average of 1 month
Mortality
Time frame: through study completion, an average of 1 month
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 May 2024.
Related trials for Acute Cholangitis
RecruitingObservational study
Composite Index for Outcome Burden in Acute Cholangitis
Acute Cholangitis, Biliary Drainage
Not yet recruiting
EUS-Guided Gallbladder Drainage Versus Conservative Management in Patients Unfit for Surgery After a Biliary Event Without Cholecystitis. DRECON Study
Cholecystectomy, Gallbladder
Not yet recruitingPhase 2
Fecal Microbiota Transplant vs Standard Treatment for Recurrent Non-Obstructive Cholangitis
Cholangitis Acute, Recurrence
RecruitingPhase 2
Comparative Efficacy Of Intraductal Antibiotic During ERCP In Acute Cholangitis
Acute Cholangitis, Biliary Tract Infection
Not yet recruiting
Impact of Positive Bile Cultures on Plastic Biliary Stent Exchange
Acute Cholangitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sang Hyub Lee, MD. PhD. principal investigator
Department of internal medicine and liver research institute, Seoul national university hospital, Seoul, Korea
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ignoring result of bile culture in people with Acute Cholangitis, run by Seoul National University Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 30 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Organ Failure (time frame: during hospitalization and empirical antibiotic administration. (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 May 2024.